Clinical Trials for Uterine Cancer

A Single-Center, Open-Label, Single-Arm, Phase I Study With Dose Expansion Cohort of Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Platinum-sensitive recurrent epithelial ovarian, fallopian tube, primary peritoneal, or endometrial cancer in adult women (PS 0–1) treated with sacituzumab govitecan (Trop-2–directed ADC delivering SN-38, a topoisomerase I inhibitor) combined with fixed-dose cisplatin every 21 days. Separate ovarian and endometrial cohorts with dose-finding followed by expansion to assess response.

ClinicalTrials.gov ID: NCT06040970

A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with recurrent mismatch repair–deficient endometrial carcinoma (non-serous, non-carcinosarcoma) after 1–2 prior lines are randomized to nivolumab (PD-1 inhibitor) plus ipilimumab (CTLA-4 inhibitor) versus nivolumab alone, including patients with treated/stable brain metastases and select stable autoimmune disease; prior PD-1/PD-L1 allowed only if part of combination therapy with ≥12-month CR interval. Treatment continues until progression/toxicity/CR with nivolumab maintenance permitted after CR.

ClinicalTrials.gov ID: NCT05112601

A Phase I/II Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial involves adults with unresectable or metastatic advanced solid tumors who have progressed on prior treatments or are candidates for pembrolizumab, combining pembrolizumab, which targets the PD-1 receptor to enhance immune response, with a personalized neoantigen peptide vaccine designed to stimulate an individualized immune attack against tumor-associated proteins.

ClinicalTrials.gov ID: NCT05269381

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable or metastatic solid tumors and ECOG performance status 0–1 receive LNCB74 monotherapy in dose-escalation and expansion cohorts. LNCB74 is an investigational B7-H4–targeted antibody–drug conjugate carrying the microtubule-disrupting payload MMAE.

ClinicalTrials.gov ID: NCT06774963

A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This study enrolls patients with unresectable or metastatic carcinoma, ECOG performance status 0–1, and a lesion available for pretreatment biopsy. Patients receive escalating or expansion doses of BMS-986463, an investigational molecular-glue degrader of the cell-cycle regulator WEE1 kinase.

ClinicalTrials.gov ID: NCT06476808

An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-112 in Human Leukocyte Antigen-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for the KRAS G12D Mutation

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with HLA-C*08:02-positive, KRAS G12D-mutant unresectable advanced or metastatic solid tumors who have received at least one approved systemic regimen and have no curative option receive a single infusion of NT-112, an autologous TCR-engineered T-cell therapy targeting KRAS G12D presented by HLA-C*08:02. Treatment includes lymphodepletion before infusion and a short course of interleukin-2 afterward.

ClinicalTrials.gov ID: NCT06218914

A Phase 1, First-in-human, Open-label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral CDK2 Degrader NKT3964 in Adults With Advanced/Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, measurable, unresectable advanced or metastatic solid tumors and ECOG 0–1 receive oral NKT3964 monotherapy, an investigational PROTAC that degrades CDK2. Expansion cohorts focus on HR-positive/HER2-negative breast cancer after CDK4/6 inhibition, CCNE1-amplified platinum-resistant or refractory ovarian cancer, and CCNE1-amplified gastroesophageal adenocarcinoma.

ClinicalTrials.gov ID: NCT06586957

A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic solid tumors, measurable disease, and ECOG performance status 0–1 receive intravenous MDX2001 monotherapy. MDX2001 is an investigational tetraspecific antibody that binds c-MET and TROP2 on tumors while engaging CD3 and providing CD28 costimulation to promote tumor-directed T-cell activity.

ClinicalTrials.gov ID: NCT06239194

A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable, advanced unresectable or metastatic solid tumors and no suitable curative treatment receive intratumoral or intravenous VET3-TGI, alone or with pembrolizumab. VET3-TGI is an oncolytic vaccinia virus engineered to express CXCR3 and IL-12 and inhibit TGF-β to promote tumor killing and antitumor immunity.

ClinicalTrials.gov ID: NCT06444815

Phase Ib/IIa Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls anthracycline-naive adults with measurable, treatment-refractory soft-tissue sarcoma, triple-negative breast cancer, non-small cell lung cancer, cervical or ovarian cancer, or KRAS-mutant pancreatic cancer after at least two prior therapies. Patients receive escalating doses of SPEDOX-6, a doxorubicin formulation encapsulated in human serum albumin that may preferentially deliver drug to tumors with low FcRn expression; FcRn testing is not required.

ClinicalTrials.gov ID: NCT07064018